ESPR Profile
Esperion Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for managing elevated levels of low-density lipoprotein cholesterol (LDL-C). The company focuses on addressing significant cardiovascular risk factors associated with high cholesterol, particularly in patients who have not achieved adequate control with current treatments. Esperion’s portfolio centers on novel medications designed to reduce LDL-C and improve cardiovascular outcomes.
The company's flagship products include NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe). NEXLETOL is an oral medication designed to lower LDL-C levels and is particularly indicated for patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH), conditions associated with high cholesterol levels and increased cardiovascular risk. NEXLIZET combines bempedoic acid with ezetimibe to provide a more comprehensive approach to cholesterol management, targeting LDL-C through complementary mechanisms to achieve more effective results.
Esperion Therapeutics has established key collaborations to advance its research and expand its therapeutic offerings. The company holds a license and collaboration agreement with Daiichi Sankyo Europe GmbH, which enhances its global reach and development capabilities. Additionally, Esperion has partnered with Serometrix to in-license an oral small molecule PCSK9 inhibitor program, further diversifying its pipeline and exploring new avenues for cholesterol management.
Founded in 2008 and headquartered in Ann Arbor, Michigan, Esperion Therapeutics operates with a mission to transform cardiovascular care through innovative treatments. The company’s focus on LDL-C reduction positions it as a leader in the field of lipid management. By advancing its pipeline of cholesterol-lowering therapies and leveraging strategic partnerships, Esperion aims to address critical unmet needs in cardiovascular health and improve patient outcomes on a global scale.
|
